HomeAgenda
Register
Register
Register

PartnershipUpdated on 14 July 2025

HOIST Corp. Ltd. seeks to license-out rights for HM-001 and ALKBH3 inhibitor

About

HOIST Corp. Ltd. is a clinical-stage biotechnology company founded in 2019 based on discoveries from The University of Osaka.

 HOIST Corp. is currently seeking partners to further develop our programs: HM-001 for bladder cancer (non-muscle invasive bladder cancer), and ALKBH3 inhibitor, currently in the pre-clinical stage for pancreatic cancer.

 HM-001 completed the Phase I portion of the Phase I/IIa clinical study, and is on schedule to initiate the Phase II portion of the study in 2H 2025.

 ALKBH3 inhibitor will be a molecular targeting drug with a new mode-of-action for cancer type with one of the biggest unmet needs: pancreatic cancer.

 We would be pleased to discuss our programs in more detail at the event.

Organisation

HOIST Corp.

Company (SME/startup) / 中小企業・スタートアップ

Minoh, Japan